Bharat Parenterals Ltd
Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations[1]
- Market Cap ₹ 721 Cr.
- Current Price ₹ 1,046
- High / Low ₹ 1,667 / 802
- Stock P/E 42.6
- Book Value ₹ 579
- Dividend Yield 0.10 %
- ROCE 11.2 %
- ROE 9.05 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 6.09% over past five years.
- Company has a low return on equity of 10.2% over last 3 years.
- Earnings include an other income of Rs.10.4 Cr.
- Dividend payout has been low at 2.32% of profits over last 3 years
- Company has high debtors of 198 days.
- Promoter holding has decreased over last 3 years: -6.65%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114 | 119 | 125 | 111 | 136 | 220 | 226 | 204 | 212 | 218 | 258 | 304 | 258 | |
| 102 | 108 | 114 | 104 | 123 | 189 | 196 | 179 | 183 | 196 | 225 | 269 | 232 | |
| Operating Profit | 12 | 11 | 10 | 7 | 13 | 30 | 30 | 25 | 29 | 22 | 33 | 35 | 26 |
| OPM % | 10% | 9% | 8% | 6% | 10% | 14% | 13% | 12% | 14% | 10% | 13% | 11% | 10% |
| -1 | 4 | 5 | 8 | 7 | 13 | 11 | 9 | 7 | 19 | 8 | 14 | 10 | |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 5 | 4 |
| Depreciation | 3 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 6 | 7 | 8 |
| Profit before tax | 6 | 9 | 9 | 8 | 14 | 36 | 35 | 27 | 28 | 32 | 31 | 36 | 23 |
| Tax % | -3% | 15% | 31% | 7% | 27% | 37% | 25% | 25% | 25% | 24% | 27% | 27% | |
| 7 | 7 | 6 | 7 | 10 | 23 | 26 | 20 | 21 | 24 | 23 | 26 | 17 | |
| EPS in Rs | 11.43 | 12.98 | 11.26 | 12.88 | 17.63 | 39.39 | 45.90 | 35.27 | 36.89 | 42.15 | 38.82 | 38.38 | 24.57 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% | 3% | 3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 13% |
| TTM: | -11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 0% |
| 3 Years: | 8% |
| TTM: | -38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 43% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 |
| Reserves | 37 | 44 | 51 | 58 | 69 | 91 | 117 | 138 | 160 | 185 | 208 | 380 | 392 |
| 21 | 16 | 19 | 6 | 9 | 5 | 1 | 12 | 15 | 46 | 83 | 65 | 18 | |
| 37 | 50 | 44 | 40 | 50 | 60 | 68 | 40 | 37 | 71 | 91 | 98 | 81 | |
| Total Liabilities | 101 | 116 | 120 | 111 | 133 | 161 | 192 | 196 | 218 | 308 | 387 | 549 | 499 |
| 29 | 29 | 35 | 31 | 34 | 35 | 33 | 45 | 41 | 36 | 39 | 46 | 47 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 12 | 0 | 1 | 0 | 0 | 5 | 5 |
| Investments | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 42 | 16 | 38 | 49 | 168 | 168 |
| 72 | 87 | 85 | 79 | 99 | 123 | 147 | 110 | 160 | 233 | 299 | 330 | 278 | |
| Total Assets | 101 | 116 | 120 | 111 | 133 | 161 | 192 | 196 | 218 | 308 | 387 | 549 | 499 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | 0 | -2 | 6 | 20 | 14 | 22 | -22 | -12 | -0 | 19 | ||
| -8 | 0 | -2 | -8 | -9 | -13 | -41 | 22 | -14 | -38 | -90 | ||
| 6 | 0 | -8 | 4 | -4 | -3 | 11 | 2 | 29 | 34 | 69 | ||
| Net Cash Flow | 2 | 0 | -11 | 2 | 7 | -1 | -8 | 2 | 3 | -5 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 126 | 179 | 129 | 144 | 158 | 109 | 132 | 122 | 126 | 188 | 198 | 198 |
| Inventory Days | 70 | 55 | 62 | 69 | 60 | 55 | 69 | 61 | 56 | 100 | 125 | 90 |
| Days Payable | 119 | 188 | 171 | 167 | 110 | 82 | 106 | 71 | 60 | 127 | 121 | 121 |
| Cash Conversion Cycle | 77 | 47 | 20 | 46 | 108 | 82 | 95 | 111 | 122 | 161 | 202 | 167 |
| Working Capital Days | 12 | 58 | 8 | 65 | 82 | 78 | 97 | 111 | 150 | 98 | 68 | 100 |
| ROCE % | 18% | 17% | 15% | 12% | 19% | 40% | 32% | 20% | 18% | 14% | 13% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 Jan - Copy of newspaper advertisement for the unaudited financial results for the quarter and nine months ended December 31, 2025.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
30 Jan - Investor Presentation for the Quarter and Nine Months Ended on December 31, 2025.
- Financial Results For The Quarter And Nine Months Ended On December 31, 2025. 30 Jan
-
Board Meeting Outcome for Outcome Of Board Meeting For The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended On December 31, 2025.
30 Jan - Q3 FY26: standalone revenue ₹41.41cr, consolidated loss ₹9.63cr; order book ₹303cr; EU GMP audit zero observations.
-
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Month Ended On December 31, 2025.
22 Jan - Board meeting on Jan 30, 2026 to approve Q3/9M Dec 31, 2025 unaudited results; trading window closed Jan 1.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2003
from bse
-
Financial Year 2002
from bse
-
Financial Year 1999
from bse
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
Business Overview:[1]
BPL is a Gujarat-based WHO GMP & an ISO 10002: 2014, 9001: 2015 certified pharmaceutical company. It manufactures over 800 products spread over 20+ different categories including General Products, β-Lactum/ Cephalosporin Products, Formulations in the form of Tablets, Capsules, Liquid- orals, Ointments, Creams, Lotions, and most importantly Powdered Injections and small Volume Parenterals both in Ampoules and Vials.